LON:TMOR More Acquisitions (TMOR) Share Price, News & Analysis → The Weight Loss Pill That Could Disrupt a $32 Billion Industry (From Behind the Markets) (Ad) Free TMOR Stock Alerts GBX 0.68 0.00 (0.00%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range 0.68▼ 0.6850-Day Range 0.45▼ 0.6952-Week Range 0.42▼ 1Volume1.00 million shsAverage Volume1.05 million shsMarket Capitalization£1.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesInsider TradesStock AnalysisChartCompetitorsHeadlinesInsider Trades Get More Acquisitions alerts: Email Address Ad Behind the MarketsCould this Tiny Biotech End Disease Forever?Imagine a revolutionary treatment capable of editing out ANY disease. By literally "cutting" the genetic instructions that cause illness, and "pasting" in corrected DNA to restore perfect health.Access my full "Cut & Paste" profit analysis now. About More Acquisitions Stock (LON:TMOR)More Acquisitions Plc operates as a blank check company. It focuses on acquiring of a target company or business in the energy transition sector. The company was incorporated in 2021 and is based in London, the United Kingdom.Read More TMOR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TMOR Stock News HeadlinesMay 3, 2024 | americanbankingnews.comMore Acquisitions (LON:TMOR) Trading Up 13%May 2, 2024 | finance.yahoo.comCUBEBIO Co., Ltd. entered into terms relating to a potential business combination with Mountain Crest Acquisition Corp. VMay 8, 2024 | Behind the Markets (Ad)The Weight Loss Pill That Could Disrupt a $32 Billion IndustryA revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.May 2, 2024 | finance.yahoo.comINTEGRATED ONCOLOGY NETWORK ANNOUNCES THE ACQUISITION OF UROLOGY PARTNERS, LLCMay 2, 2024 | bizjournals.comHologic adds to breast surgery tech with $310M acquisitionMay 1, 2024 | tmcnet.comRadformation to Accelerate AI-Based Solutions with Limbus AI AcquisitionApril 25, 2024 | msn.comBristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion AcquisitionsApril 25, 2024 | finance.yahoo.com20 Counties with the Highest Cancer Rates in the USMay 8, 2024 | Behind the Markets (Ad)The Weight Loss Pill That Could Disrupt a $32 Billion IndustryA revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.April 23, 2024 | finance.yahoo.comPancreatic Cancer Pipeline Market Research 2024: Comprehensive Insights on More than 290 Companies and their Associated 300+ Pipeline DrugsApril 22, 2024 | msn.comJohnson & Johnson acquisitions hit close to $15bnApril 18, 2024 | msn.comBreakthrough imaging method enhances precision in prostate cancer treatmentApril 16, 2024 | msn.comNew SPECT/CT technique shows impressive biomarker identification, offers increased access for prostate cancer patientsApril 11, 2024 | seekingalpha.comJanux Therapeutics: A Prime Target In Cancer Care's M&A GameApril 10, 2024 | msn.comWindtree Therapeutics Takes a Bold Stride in Oncology with Varian Assets AcquisitionApril 8, 2024 | msn.comBristol Myers releases encouraging data for Krazati in colorectal cancerApril 8, 2024 | msn.comAdAlta and SYNthesis to form AdCella for advanced cancer treatmentsApril 3, 2024 | msn.comGenmab to Buy Cancer Drug Developer for $1.8 BillionApril 1, 2024 | msn.comDaily horoscope for April 1, 2024: Good day for Leo, health of Virgo may be affected & moreMarch 25, 2024 | msn.comFDA Delays Decision For Regeneron's Inaugural Blood Cancer Therapy, Highlights Trial ConcernsMarch 20, 2024 | msn.comAstra to Buy Fusion Pharma in Hunt for New Cancer TreatmentsMarch 19, 2024 | msn.comAstraZeneca bets on next-generation cancer therapy with $2 billion Fusion dealMarch 19, 2024 | mirror.co.ukAstraZeneca buys Canadian cancer treatment firm for close to £2 billionMarch 19, 2024 | thetimes.co.ukAstraZeneca acquires next-generation cancer treatmentsMarch 19, 2024 | seekingalpha.comWhat AstraZeneca Is Getting Through The Acquisition Of Fusion PharmaceuticalsMarch 19, 2024 | stockhouse.comAstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancerMarch 19, 2024 | msn.comAstraZeneca snaps up rival to develop pioneering new cancer treatmentSee More Headlines Receive TMOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for More Acquisitions and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorFinancial Services Industry Shell Companies Sub-IndustryN/A Current SymbolLON:TMOR CUSIPN/A CIKN/A Webwww.moreacquisitions.co.uk PhoneN/AFaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares160,720,000Free FloatN/AMarket Cap£1.08 million OptionableNot Optionable BetaN/A 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Roderick Claude McIllree B.Sc. (Age 49)BSc., MAusIMM, Exec. Director Mr. Charles Edouard Goodfellow (Age 66)Non-Exec. Director & Sec. Key CompetitorsBeacon RiseLON:BRSElectric GuitarLON:ELEGMining, Minerals & MetalsLON:MMMBecket InvestLON:TABBoston InternationalLON:BIHView All CompetitorsInsidersRoderick McIllreeBought 7,250,000 shares on 6/1/2023Total: £7.25 M ($1.00/share)View All Insider Transactions TMOR Stock Analysis - Frequently Asked Questions How have TMOR shares performed in 2024? More Acquisitions' stock was trading at GBX 0.50 at the beginning of 2024. Since then, TMOR shares have increased by 35.8% and is now trading at GBX 0.68. View the best growth stocks for 2024 here. How do I buy shares of More Acquisitions? Shares of TMOR stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:TMOR) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorFidelity, Bezos, Goldman Bet Big on Tiny BiotechBehind the MarketsAI “wealth window” is closing June 25thParadigm PressElon Musk Secret Crypto Plot ExposedCrypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressThe #1 lithium battery stock to have on your radar in 2024!Smallcaps Daily Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding More Acquisitions Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
